comparemela.com

Sia Daneshmand, MD, discusses the rationale for investigating TAR-200 for the treatment of patients with Bacillus Calmette-Guérin-unresponsive, high-risk non–muscle-invasive bladder cancer, expands on the preliminary efficacy and safety data from the SunRISe-1 trial, and more.

Related Keywords

Chicago ,Illinois ,United States ,California ,University Of Southern California ,American ,Los Angeles ,American Urological Association ,Clinical Research ,Bacillus Calmette Gu ,Sia Daneshmand ,Urological Association ,Annual Meeting ,Urologic Oncology Fellowship ,Keck Medicine ,Southern California ,Urologic Oncology ,Urothelial Cancer ,News ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.